About

BIGESPAS Ltd, is a UK based private company established in 2020 to run an anti-Alzheimer drug development project. The company holds an international patent WO 2022/160066 А1 which secures a know-how related to the discovered polymorph DMB-I of Latrepirdine.

In 2022 BIGESPAS Ltd acquired a control over Dimebon® medicine (INN Latrepirdine) to facilitate the product development.

In 2023 BIGESPAS Ltd has started Phase II trial on its drug product Dimebon® DMB-I based on successful data received on an animal studies stage.